Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Bensinger

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|December 16, 2010
The treatment of elderly patients with multiple myeloma: is more better?William Bensinger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2007
Stem-cell transplantation for multiple myeloma in the era of novel drugsWilliam Bensinger
Current Treatment Options in Oncology|August 28, 2007
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell TransplantationWilliam Bensinger
Hematology/Oncology Clinics of North America|September 13, 2014
Allogeneic stem cell transplantation for multiple myelomaWilliam Bensinger
Acta Haematologica|November 5, 2005
Improved conditioning regimens for autologous transplantation using targeted radiotherapyXingwei Sui, William Bensinger, Oliver Press
Clinical Lymphoma & Myeloma|October 10, 2006
Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphomaLeona A Holmberg, David Maloney, William Bensinger
Acta Haematologica|March 30, 2017
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and ClarithromycinLeona A Holmberg, Pamela S Becker, William Bensinger
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimationJoseph G Rajendran, Janet F Eary, William Bensinger, et al.
Journal of Hematology & Oncology|January 8, 2013
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsMohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, et al.
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|December 16, 2010
The treatment of elderly patients with multiple myeloma: is more better?William Bensinger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2007
Stem-cell transplantation for multiple myeloma in the era of novel drugsWilliam Bensinger
Current Treatment Options in Oncology|August 28, 2007
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell TransplantationWilliam Bensinger
Hematology/Oncology Clinics of North America|September 13, 2014
Allogeneic stem cell transplantation for multiple myelomaWilliam Bensinger
Acta Haematologica|November 5, 2005
Improved conditioning regimens for autologous transplantation using targeted radiotherapyXingwei Sui, William Bensinger, Oliver Press
Clinical Lymphoma & Myeloma|October 10, 2006
Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphomaLeona A Holmberg, David Maloney, William Bensinger
Acta Haematologica|March 30, 2017
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and ClarithromycinLeona A Holmberg, Pamela S Becker, William Bensinger
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimationJoseph G Rajendran, Janet F Eary, William Bensinger, et al.
Journal of Hematology & Oncology|January 8, 2013
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsMohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, et al.
Journal of Hematology & Oncology|April 5, 2018
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyMeletios Dimopoulos, Michael Wang, Vladimir Maisnar, et al.
Pageof 5